Neurological disorders such as autism spectrum disorder (ASD), Parkinson’s disease (PD), Alzheimer’s disease (AD), Cardio-Facio-cutaneous (CFC), and Noonan syndromes (NS) have been linked to abnormalities in the regulation of the MAPK signaling pathway.50 Moreover, the RAS/RAF/MAPK pathway is gaining attention as a potential target for the development of novel anti-inflammatory drugs, with implications for conditions like rheumatic arthritis (RA)51, inflammatory bowel disease (IBD)52 and pulmonary fibrosis (PF).53 Here, RAF1 is linked to Alzheimer disease.